Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Second Quarter (Q2) and First Half (H1) ended June 30, 2003
Filing Date: March 4, 2004
GSK is a leading research-based pharmaceutical and healthcare company. The results are reported in sterling and are significantly influenced by exchange rate movements against the US dollar, Euro, and Japanese Yen. The company utilizes Constant Exchange Rate (CER) growth to illustrate underlying performance.
Key Financial Metrics
| Metric (Q2 2003) | Value (£m) | CER Growth % | Sterling Growth % |
|---|---|---|---|
| Turnover | 5,375 | 3% | (1%) |
| Trading Profit | 1,801 | 16% | 11% |
| Operating Profit | 1,888 | 21% | 15% |
| Profit Before Tax | 1,882 | 21% | 15% |
| Earnings (Net Profit) | 1,330 | 19% | 13% |
| Earnings Per Share (Basic) | 22.8 p | 22% | 16% |
| Operating Cash Flow | 1,694 | - | - |
| Net Debt (End of Period) | (2,162) | - | - |
Note: Negative net debt indicates a net cash position or debt reduction relative to cash holdings in the reconciliation context, though the table lists it as a liability figure in the source text. The text states net debt at end of period was £2,162m.
Material Changes vs. Prior Period
- Currency Impact: Stronger sterling against the US dollar and Yen, but weaker against the Euro, resulted in an overall adverse currency impact. Turnover fell 1% in sterling terms despite 3% CER growth.
- Profitability: Trading margin improved by 3.5 percentage points to 33.5% of turnover. This was driven by a 2% CER decrease in cost of sales and a 6% CER decrease in selling, general, and administration (SG&A) costs, offsetting a 9% CER increase in R&D expenditure.
- Product Performance:
- Pharmaceuticals: Seretide/Advair sales grew 31% CER (£531m). Seroxat/Paxil sales were flat in CER terms (£520m). Augmentin sales declined 42% CER due to generic competition.
- Consumer Healthcare: Nutritional healthcare grew 12% CER, while Oral Care declined 2% CER.
- Dividends: The Board declared a second interim dividend of 9 pence per share, consistent with Q2 2002.
Outlook, Risks, and Contingencies
- Taxation Dispute (Material Contingency): On January 7, 2004, GSK received a statutory notice of deficiency from the US IRS for the years 1989–1996 claiming $2.7 billion (£1.5 billion) in additional taxes. GSK estimates potential interest on this claim at approximately $2.5 billion (£1.4 billion). The company plans to contest this in the US Tax Court, with a trial expected in 2005 or 2006. GSK believes it has made adequate provision for likely liabilities.
- Legal Proceedings:
- Intellectual Property: Ongoing litigation regarding patents for Paxil (paroxetine), Wellbutrin, Zofran, and Avandia. Generic versions of Paxil and Wellbutrin have launched in the US following court rulings and settlements.
- Antitrust: Settlements reached regarding nabumetone (Relafen) totaling $175 million. Paxil antitrust cases are scheduled for trial in December 2004.
- Product Liability: Class certification denied for Paxil addiction claims in California.
- Regulatory: The FDA is investigating GSK's manufacturing facility in Cidra, Puerto Rico, issuing two Forms 483 regarding production controls. No indication of supply disruption has been received.
- Share Buyback: GSK is executing a £4 billion share buyback programme. £275 million was spent in Q2 2003.
Investor Verification Checklist
- IRS Tax Claim: Verify the status of the $2.7 billion tax dispute and the adequacy of current provisions against the potential $2.5 billion interest liability.
- Patent Expirations: Monitor the impact of generic entry for Paxil and Wellbutrin on future revenue streams, particularly in the US market.
- Currency Sensitivity: Assess the exposure to sterling strength against the US dollar, which continues to negatively impact reported turnover and earnings.
- Manufacturing Compliance: Track the resolution of the FDA investigation at the Puerto Rico facility to ensure no future supply chain disruptions.
- US GAAP Reconciliation: Note the significant difference between UK GAAP earnings (£1,330m for Q2) and US GAAP net income (£1,768m for H1, or approx. £884m for Q2 pro-rata), primarily due to amortization of intangible assets and stock-based compensation.